

Pfizer Research Grant – Request for Proposals (RFP) *Interventional Research Studies with Elranatamab*

Competitive Grant Program –Pfizer Internal Review Process



Overview

Pfizer supports Investigator Sponsored Research (ISR) projects that advance medical and scientific knowledge about our therapies.

An ISR is a type of grant that supports an independent research study where the investigator or organization is the sponsor of the study and where Pfizer provides financial and/or non-financial support for the development or refinement of specific and defined medical knowledge relating to a Pfizer asset. This global program is open to all researchers who are interested in conducting their own research.



Geographic Scope

Global



Area of Interest

Studies that will be considered for Pfizer financial and non-financial support will focus on generating evidence on priority gaps in the use of elranatamab in multiple myeloma across lines of treatment. See full details in the General Area of Interest Section in the page below.



Key Milestones

- Application submission deadline: **July 18, 2024**
- Anticipated decision notification date: **August 26, 2024**
- Anticipated project start date: **January 2025**



Funding Range

Individual study grant requests up to \$1.5 million USD will be considered, although smaller requests (around \$500,000) are also encouraged.

If there is strong scientific justification and well-supported in the budget details, applicants may request up to a maximum of \$2 million per study.

The estimated total available budget related to this RFP is \$6 million USD.

I. Eligibility

Geographic Scope/Location of Project/Study:

- Global

Applicant Eligibility Criteria

- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (e.g. BSN with a MS/PhD), or a terminal degree in Pharmacy or other healthcare field.
- The grant applicant must be the PI or an authorized designee of such individual (e.g., PI's research coordinator).
- The PI must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application.

II. Requirements

Date RFP Issued

- June 7, 2024

Clinical Area

- Oncology – Hematology – Multiple Myeloma

General Area of Interest for this RFP:

- Projects that will be considered for Pfizer support will focus on generating evidence on priority gaps in the use of elranatamab in multiple myeloma across lines of treatment, and in particular:
 - Combination with novel agents
 - Frontline use of elranatamab in newly diagnosed multiple myeloma, including sequencing with autologous Stem-Cell Transplant (ASCT)/Chimeric Antigen Receptor T-cells (CAR-T), focus on subpopulations of unmet needs, segmentation based on disease biology
 - Optimal administration of elranatamab treatment in patient subpopulations based on patients (e.g. age/fitness/comorbidities), risk (e.g. HRCA, extramedullary disease, high tumor burden) and response characteristics
 - Characterization, monitoring, and mitigation strategies of: Infections, CRS, Neurotoxicity/ ICANS, viral reactivation (incl. observing and monitoring emerging infections), other adverse events of elranatamab treatment
 - Investigation and intervention of resistance/relapse mechanisms to elranatamab treatment, with focus on strategies to mitigate T-cell exhaustion and its clinical outcomes
 - Retreatment-rechallenging strategies

Expected Approximate Monetary Range of Grant Applications:

- Individual study grant requests up to \$1.5 million USD will be considered, although smaller requests (around \$500,000) are also encouraged.
If there is strong scientific justification and well-supported in the budget details, applicants may request up to a maximum of \$2 million per study.
- The estimated total available budget related to this RFP is \$6 million USD.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Key Dates:

- Grant Application due date: **Thursday, July 18, 2024**
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: **Monday, August 26, 2024**
- Grants will be distributed following a fully executed agreement and submission of Final Protocol, documentation of IRB/IEC approval, regulatory approval (if applicable), exemption or waiver.
- Contracting and IRB Review Period: **September 2024 to December 2024**
- Anticipated Project Start Date: **January 2025**

How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Please go to www.cybergrants.com/pfizer/Research and sign in. First-time users should click “Create your password”. *[Note: there are individual portals for each grant application type. Please be sure to use the URL above.]*
- Click the "Start a New Research Grant Application" button.
- In the application:
 - For the question “Competitive Grant?” select Yes
- Select the following Competitive Grant Program Name: 2024 ONC Global Interventional Research Studies with Elranatamab RES
 - Select the following Primary Area of Interest: Oncology – Hematology – Multiple Myeloma
- Requirements for submission:
Complete all required sections of the online application and upload your project proposal (see Appendix) in the Proposal/Protocol field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:

- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jacqueline Waldrop (Jacqueline.Waldrop@pfizer.com), with the subject line “RFP - Interventional Research Studies with Elranatamab June 2024.”
- Please click [here](#) to view Frequently Asked Questions regarding the Competitive Grant Program.

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.
- This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Appendix

General RFP Submission Requirements

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Project Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is no page limit for this RFP. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective.

Assessment of Need for the Project

- This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question.

Target Audience

- Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population.
- Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods

- Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan.

Innovation

- Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.

Evaluation and Outcomes

- Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures.
- Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.
 - An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.
- Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant's career.

Organization Detail

- This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and “other”]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project.

Budget Detail

- The budget amount requested must be in U.S. dollars (USD).
- While estimating your budget please keep the following items in mind:
 - General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.
 - The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
 - Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.
 - It should be noted that grants awarded through GMG cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription).
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please [click here](#) for details.